These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36781824)

  • 1. Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects.
    Fishman P; Stemmer SM; Bareket-Samish A; Silverman MH; Kerns WD
    Purinergic Signal; 2023 Sep; 19(3):513-522. PubMed ID: 36781824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial.
    Stemmer SM; Manojlovic NS; Marinca MV; Petrov P; Cherciu N; Ganea D; Ciuleanu TE; Pusca IA; Beg MS; Purcell WT; Croitoru AE; Ilieva RN; Natošević S; Nita AL; Kalev DN; Harpaz Z; Farbstein M; Silverman MH; Bristol D; Itzhak I; Fishman P
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33430312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A long‑term complete response to namodenoson in liver cancer with Child‑Pugh B cirrhosis: A case report.
    Ciurescu IA; Lencioni R; Stemmer SM; Farbstein M; Harpaz Z; Bareket-Samish A; Silverman MH; Fishman P
    Exp Ther Med; 2024 Jun; 27(6):263. PubMed ID: 38756903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data.
    Fishman P
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35744805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma.
    Etzion O; Bareket-Samish A; Yardeni D; Fishman P
    Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis.
    Safadi R; Braun M; Francis A; Milgrom Y; Massarwa M; Hakimian D; Hazou W; Issachar A; Harpaz Z; Farbstein M; Itzhak I; Lev-Cohain N; Bareket-Samish A; Silverman MH; Fishman P
    Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1405-1415. PubMed ID: 34671996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.
    Stemmer SM; Benjaminov O; Medalia G; Ciuraru NB; Silverman MH; Bar-Yehuda S; Fishman S; Harpaz Z; Farbstein M; Cohen S; Patoka R; Singer B; Kerns WD; Fishman P
    Oncologist; 2013; 18(1):25-6. PubMed ID: 23299770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice.
    Fishman P; Cohen S; Itzhak I; Amer J; Salhab A; Barer F; Safadi R
    Int J Mol Med; 2019 Dec; 44(6):2256-2264. PubMed ID: 31638172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
    Rimassa L; Assenat E; Peck-Radosavljevic M; Pracht M; Zagonel V; Mathurin P; Rota Caremoli E; Porta C; Daniele B; Bolondi L; Mazzaferro V; Harris W; Damjanov N; Pastorelli D; Reig M; Knox J; Negri F; Trojan J; López López C; Personeni N; Decaens T; Dupuy M; Sieghart W; Abbadessa G; Schwartz B; Lamar M; Goldberg T; Shuster D; Santoro A; Bruix J
    Lancet Oncol; 2018 May; 19(5):682-693. PubMed ID: 29625879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits.
    Chiu J; Tang YF; Yao TJ; Wong A; Wong H; Leung R; Chan P; Cheung TT; Chan AC; Pang R; Fan ST; Poon R; Yau T
    Cancer; 2012 Nov; 118(21):5293-301. PubMed ID: 22517493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/β-catenin, NF-κB, and RAS Signaling Pathways.
    Itzhak I; Bareket-Samish A; Fishman P
    Biomolecules; 2023 Oct; 13(11):. PubMed ID: 38002266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.
    Thiruvengadam S; Bauer KE; Bracci PM; Keenan BP; Behr SC; Gordan JD; Kelley RK
    Cancer; 2019 Sep; 125(18):3234-3241. PubMed ID: 31154669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
    Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial.
    El-Khoueiry AB; Meyer T; Cheng AL; Rimassa L; Sen S; Milwee S; Kelley RK; Abou-Alfa GK
    BMC Cancer; 2022 Apr; 22(1):377. PubMed ID: 35397508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
    Kim HY; Park JW; Joo J; Kim H; Woo SM; Lee WJ; Kim CM
    J Gastroenterol Hepatol; 2013 Nov; 28(11):1756-61. PubMed ID: 23800278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
    Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
    Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlotinib for advanced hepatocellular carcinoma. A systematic review of phase II/III clinical trials.
    Zhang J; Zong Y; Xu GZ; Xing K
    Saudi Med J; 2016 Nov; 37(11):1184-1190. PubMed ID: 27761555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.